Study of Ambrisentan in Participants With Pulmonary Hypertension
Public ClinicalTrials.gov record NCT00777920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to monitor the long-term safety of ambrisentan in adult participants with pulmonary hypertension. The available ambrisentan doses for this study are 2.5, 5, or 10 mg administered orally once daily. Investigators will be able to adjust ambrisentan dose as clinically indicated. A minimum of 4 weeks between dose adjustments is required. Participants receiving other therapies for pulmonary hypertension that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in this study and continue to receive such therapies. Participants enrolled in this study will receive treatment with ambrisentan until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
Study identification
- NCT ID
- NCT00777920
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2008
- Primary completion
- Sep 10, 2019
- Completion
- Sep 10, 2019
- Last update posted
- Sep 29, 2020
2008 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Arizona Pulmonary Specialists | Phoenix | Arizona | 85013 | — |
| University of Colorado Health Science Center | Aurora | Colorado | 80045 | — |
| University of Connecticut Health Center | Farmington | Connecticut | 06030 | — |
| Atlanta Institute for Medical Research, Inc. | Atlanta | Georgia | 30030 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| BACH Cardiology/Children's Hospital | Boston | Massachusetts | 02115 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Newark Beth Israel Medical Center | Newark | New Jersey | 07112 | — |
| Mary Parkes Asthma Center University of Rochester | Rochester | New York | 14623 | — |
| University of Pittsburgh Medical Center Presbyterian | Pittsburgh | Pennsylvania | 15213 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Lexington Pulmonary and Critical Care Medicine | Lexington | South Carolina | 29072 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00777920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2020 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00777920 live on ClinicalTrials.gov.